Table 4.

Risk factors for injury per faint

Population	Size, n	Injuries, n	Mean risk (CI)	Relative risk (CI)	P-value
Total	710	102	0.14 (0.12–0.17)
Sex
Male	154	23	0.15 (0.10–0.21)	1.05 (0.68–1.61)	0.82
Female	556	79	0.14 (0.12–0.17)
Age
<Median	346	51	0.15 (0.11–0.19)	1.05 (0.74–1.51)	0.39
>Median	364	51	0.14 (0.11–0.18)
Population type
Bifascicular block	37	10	0.27 (0.15–0.43)	1.98 (1.13–3.47)	0.018
Vasovagal	673	92	0.14 (0.11–0.17)
Prior year, n
<Median	74	16	0.22 (0.14–0.32)	1.60 (0.99–2.57)	0.027
>Median	636	86	0.14 (0.11–0.16)
Prodrome
Absent	116	29	0.25 (0.18–0.34)	1.60 (0.91–2.81)	0.10
Present	96	15	0.16 (0.10–0.24)
Drug therapy
Placebo	360	59	0.16 (0.13–0.21)
Active	313	33	0.11 (0.08–0.15)	0.64 (0.43–0.96)	0.015
Device therapy
ILR	11	5	0.40 (1.1–10.2)
Pacemaker	10	4	0.45 (1.6–11.7)	1.1 (0.42–3.1)	0.8

Size, n is the number of faints. Injured, n is the number of faints resulting in an injury. The mean age in the total study population was 45 and the median number of faints in the year before randomization was 3. Prodromal symptoms were recorded in POST 3 and 4. The bifascicular heart block population was in POST 3 and the vasovagal population was in POST 2 and 4.

CI, confidence interval; ILR, implantable loop recorder.